Specifically, small-molecule PDE4 inhibitors, which forestall cAMP degradation, have manifested robust efficacy across a broad spectrum of inflammatory diseases, including but not limited to Inflammatory Bowel Disease, Atopic Dermatitis, and Rheumatoid Arthritis (33, 34). This evidence concerns the gene PDE4A and atopic eczema.